Javed Khan, Shikha Yadav* and Md. Aftab Alam Pages 2640 - 2654 ( 15 )
Cardiovascular diseases (CVDs) are a leading cause of death and disability worldwide. Given the current challenges in recognizing and managing CVDs, the initial and long-term outcomes of patients vary substantially despite recent breakthroughs in the treatment of CVDs. Due to a deficiency of cutting-edge diagnostics and individually targeted treatments, innovative and out-of-the-box strategies are required to close this chasm. Nanotechnology allows the development of nanomaterials with the potential to enhance health and treat disease. Particularly, nanotechnologies have recently come to be seen as having a future for the management of chronic illnesses including cancers and cardiovascular disorders (CVDs). Nanoparticle drug carriers, which have the potential to increase the pharmaco-efficiency and safety of conventional treatments, are an area of great interest. The use of nanomaterials as drug carriers in CVDs has been proposed in a number of different ways, but there are now ongoing debates on which nanomaterials and nanoformulation should be used. Accordingly, the focus in the current study is on the application of nanoparticles to cardiovascular diseases and the administration of medications using nanomedicine.
Cardiovascular diseases, nanoparticles, nanomedicine, nanocarriers, targeted drug delivery, nanotoxicity.